A-423,579

A-423,579
Nazivi
	IUPAC naziv 4-(43-[3-(Dimetilamino)pirolidin-1-il]propoksi3,5-difluorofenil)benzonitril
Identifikacija
CAS broj	461045-17-0 ;
3D model (Jmol)	interaktivna slika; interaktivna slika;
ChemSpider	9524593 (R) ; 13210784 ;
PubChem C ID	11349657 (R); 22994515;
	SMILES CN(C)C1CCN(CCCOC2=C(F)C=C(C=C2F)C2=CC=C(C=C2)C#N)C1; CN(C)C1CCN(CCCOc2c(F)cc(cc2F):c2ccc(cc2)C#N)C1; ; ; ; ;
Svojstva
Hemijska formula	C22H25F2N3O
Molarna masa	385,4502 g mol-1
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

A-423,579 je histaminski antagonist koji je razvila kompanija Abot laboratorije. On je selektivan za H₃ receptor, i ima stimulantno i anoreksično dejstvo u životinjskim studijama, te je potencijalno koristan tretman za gojaznost. A-423,579 ima poboljšane karakteristike u odnosu na druge ranije razvije lekove ove serije. On ima veću efikasnost i nižu toksičnost u istraživanjima na miševima, i trenutno je u kliničkom razvoju.^[3]^[4]

Reference уреди

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB (2004). „In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists”. Basic Clin. Pharmacol. Toxicol. 95 (3): 144—52. PMID 15447739. doi:10.1111/j.1742-7843.2004.950307.x.
^ Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB (2005). „Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy”. Inflamm. Res. 54 Suppl 1: S27—9. PMID 15928821. doi:10.1007/s00011-004-0412-z.

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[3] Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB (2004). „In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists”. Basic Clin. Pharmacol. Toxicol. 95 (3): 144—52. PMID 15447739. doi:10.1111/j.1742-7843.2004.950307.x.

[4] Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB (2005). „Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy”. Inflamm. Res. 54 Suppl 1: S27—9. PMID 15928821. doi:10.1007/s00011-004-0412-z.

[3]

[4]

[1]

[2]